Get the Stockscreener App
32.12
7.09%
-2.45
After Hours:
31.88
-0.24
-0.75%
Structure Therapeutics Inc Adr stock is traded at $32.12, with a volume of 971.70K.
It is down -7.09% in the last 24 hours and down -3.60% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$34.57
Open:
$34.1
24h Volume:
971.70K
Relative Volume:
0.87
Market Cap:
$1.86B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-14.47
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-6.00%
1M Performance:
-3.60%
6M Performance:
+47.41%
1Y Performance:
-5.36%
1-Day Range:
$31.98
$35.15
1-Week Range:
$31.98
$36.09
52-Week Range:
$13.22
$40.29
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
32.12 | 2.10B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Structure Therapeutics stock: Stifel reiterates Buy rating ahead of key data - Investing.com UK
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Envestnet Asset Management Inc. Buys Shares of 10,676 Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Behavioral Patterns of GPCR and Institutional Flows - news.stocktradersdaily.com
5 Argument Sessions Bias Attys Should Watch In Dec. - Law360
A better buy-in window may exist right now for Structure Therapeutics Inc ADR (GPCR) - Setenews
Promising Potential of Structure Therapeutics’ Aleniglipron in the Incretin-Based Therapy Landscape - TipRanks
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists - TipRanks
Calif. Forecast: Tribe To Make Sovereignty Args In Labor Suit - Law360
Top investors say Five Below Inc (FIVE) ticks everything they need - Setenews
Structure Therapeutics Reports Q3 2025 Financial Results - MSN
Buy Rating on Structure Therapeutics, Inc. Driven by Aleniglipron’s Potential in the Obesity Market - TipRanks
Avago, Google among market cap stock movers on Wednesday By Investing.com - Investing.com Nigeria
Avago, Google among market cap stock movers on Wednesday - Investing.com India
Structure Therapeutics Inc ADR (GPCR) is looking forward to a strong quarter - Setenews
Nothing is Better Than Organon & Co (OGN) stock at the moment - Setenews
Structure Therapeutics stock hits 52-week high at 37.66 USD By Investing.com - Investing.com Nigeria
Structure Therapeutics stock hits 52-week high at 37.66 USD - Investing.com
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts - Finviz
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Oral Proteins and Peptides Market Know the Scope and Trends - industrytoday.co.uk
Why Structure Therapeutics Shares Are On The Rise - TipRanks
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Nothing is Better Than Structure Therapeutics Inc ADR (GPCR) stock at the moment - Setenews
Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zymeworks (ZYME), MBX Biosciences, Inc. (MBX) and Lemaitre Vascular (LMAT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Astrana Health (ASTH) and Viatris (VTRS) - The Globe and Mail
Decoding Structure Therapeutics Inc (GPCR): A Strategic SWOT Ins - GuruFocus
Entero Therapeutics’ Board Governance Structure Update - The Globe and Mail
Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position - TipRanks
Structure Therapeutics : Corporate Presentation (November 2025) - MarketScreener
[8-K] Structure Therapeutics Inc. Reports Material Event | GPCR SEC FilingForm 8-K - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) on track for 36-week GLP-1 data year-end 2025 - Stock Titan
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - The Globe and Mail
CapEx per share of Structure Therapeutics, Inc. Sponsored ADR – NASDAQ:GPCR - TradingView
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Wall Street analysts’ outlook for Structure Therapeutics Inc ADR (GPCR) - setenews.com
Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Pier Capital LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.2%Still a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics - TipRanks
What is Structure Therapeutics Inc ADR (GPCR) Stock Return on Shareholders’ Capital? - Setenews
11,000 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by Allianz Asset Management GmbH - MarketBeat
Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Allianz Asset Management GmbH Purchases New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - Defense World
Jazz Pharmaceuticals (NASDAQ: JAZZ) names Ted W. Love, M.D., to board Dec 1, 2025 - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - NewsBreak: Local News & Alerts
Critical Survey: Alkermes (NASDAQ:ALKS) and Structure Therapeutics (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):